liver cancer

Published in the "elements of cancer treatment," the journal of a study showed that using RNA interference (RNAi) lowered plasma urokinase-type plasminogen activator (u-PA) expression, can reduce the ability of liver cancer cell migration, invasion of and proliferative capacity, is expected to become a new type of gene therapy for liver cancer means.
Italy Salvi A University of Brescia and colleagues pointed out that the serine protease category u-PA and a variety of physiological and pathological processes related, but in the u-PA mRNA expression in human hepatocellular carcinoma specimens upward, and with the prognosis of patients with related .
RNA interference research personnel through technology, research u-PA infiltration of liver cancer in the role.Choose high expression of u-PA SKHep1C3 hepatocellular carcinoma cell line, produced by small interfering RNA (siRNA), multi-step process of inhibiting gene expression:SKHep1C3 cells in the interim with the reverse contains 19 amino acid sequence of U6 promoter plasmid, in order to regulate the expression of u-PA.The results showed that the stable transfected cell u-PA expression continued to drop, while its migration, invasion and proliferation of decline.
Salvi Dr. considers that the use of RNAi technology reduced expression of u-PA, can reduce the ability of liver cancer cell migration, proliferation and infiltration capacity, is expected to a new type of gene therapy for liver cancer means.